Add time:09/01/2019         Source:sciencedirect.com

A new sulfonamide, sulfacytine, was compared in a double-blind study with sulfisoxazole in 132 patients with uncomplicated urinary tract infections. At the doses used, I Gm. per day of sulfacytine or 4 Gm. per day of sulfisoxazole, bacteriologic success (decrease of pathogenic organisms from ⪖ 100,000 to ⩽ 1,000 per milliliter of urine) was demonstrated in approximately 90 per cent of the patients. Clinical success (subsidence of the symptoms, frequency of urination, and dysuria, and reduction of pyuria from ⪖ 10 to < 10 white blood cells per high-powers field) occurred in 85 to 90 percent. Six patients in the sulfacytine group and 9 in the sulfisoxazole group reported adverse experiences. Drug was discontinued or administration interrupted because of adverse experiences in 4 sulfacytine patients and 6 sulfisoxazole patients. Laboratory values generally remained normal, but 1 patient in each medication group had decreases in white blood cells that might have been attributable to drug. On the basis of this study sulfacytine appears to be an effective drug for the treatment of uncomplicated urinary tract infections.

We also recommend Trading Suppliers and Manufacturers of Sulfacytine (cas 1401-49-6). Pls Click Website Link as below: cas 1401-49-6 suppliers